Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.82 |
| ▸ | RET | P07949 | 4/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.82 |
| ▸ | FLT4 | P35916 | 2/20 | 0.82 |
| ▸ | TEK | Q02763 | 2/20 | 0.82 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.82 |
| ▸ | PLK4 | O00444 | 1/20 | 0.82 |
| ▸ | GAK | O14976 | 1/20 | 0.82 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.82 |
| ▸ | ERN1 | O75460 | 1/20 | 0.82 |
| ▸ | STK10 | O94804 | 1/20 | 0.82 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.82 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.82 |
| ▸ | ABL1 | P00519 | 1/20 | 0.82 |
| ▸ | EGFR | P00533 | 1/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.82 |
| ▸ | LCK | P06239 | 1/20 | 0.82 |
| ▸ | FYN | P06241 | 1/20 | 0.82 |
| ▸ | CSF1R | P07333 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198096 | 0.91 | KDR (0.89) | KDRRETPDGFRBFLT4TEK | |
| SCHEMBL13471998 | 0.91 | KDR (0.89) | KDRRETPDGFRBFLT4TEK | |
| SCHEMBL1401668 | 0.91 | KDR (0.89) | KDRRETPDGFRBFLT4TEK | |
| Cediranib SCHEMBL29383181 | 0.90 | KDR (1.00) | KDRRETPDGFRBFLT4TEK | |
| Cediranib SCHEMBL29368143 | 0.90 | KDR (1.00) | KDRRETPDGFRBFLT4TEK | |
| Cediranib SCHEMBL63147 | 0.90 | KDR (1.00) | KDRRETPDGFRBFLT4TEK | |
| Cediranib SCHEMBL29351458 | 0.90 | KDR (1.00) | KDRRETPDGFRBFLT4TEK | |
| SCHEMBL1685423 | 0.90 | ABCB11 (1.00) | KDRRETPDGFRBFLT4TEK | |
| SCHEMBL1401641 | 0.89 | KDR (0.88) | KDRRETPDGFRBFLT4TEK | |
| SCHEMBL14421787 | 0.89 | KDR (0.88) | KDRRETPDGFRBFLT4TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | claimed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | claimed |
| US-20080027069-A1 | Quinazoline compounds | ASTRAZENECA AB | 2008-01-31 | — | — | US | claimed |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | claimed |
| EP-1620104-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | Astrazeneca AB (SE) | 2006-02-01 | — | — | EP | claimed |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | claimed |
| WO-2004098604-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | claimed |
| EP-1474420-A1 | QUINAZOLINE COMPOUNDS | Astrazeneca AB (SE) | 2004-11-10 | — | — | EP | claimed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | claimed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| EP-1620104-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | Astrazeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | disclosed |
| WO-2004098604-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | SRC, TEK, FLT4 | KDR 5/4885RET 145/4885PDGFRB 18/4885 |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | VEGFA, FLT4, FLT1 | KDR 4/4885RET 3578/4885PDGFRB 1557/4885 |
| US-20080027069-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | KDR 5/4885RET 2725/4885PDGFRB 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.